Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company's stock closed at $12.26 on October 2nd, with an after-hours price of $12.28, and has seen a 36.37% year-to-date return. Intellia Therapeutics is actively engaged in collaborations for developing in vivo and ex vivo therapies for various diseases, including transthyretin amyloidosis and hereditary angioedema.
Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now?
Intellia Therapeutics (NTLA) is drawing fresh attention after recent price movements, closing at US$12.06, with a year-to-date return of 30.94% despite a 41% decline over the past year. The company's clinical-stage CRISPR pipeline and collaboration footprint are key factors, with a fair value estimate of $23.94 suggesting it's undervalued due to promising late-stage clinical trial enrollment and potential commercialization. However, a high P/S ratio of 28.4x compared to the industry average indicates potential valuation risk.
No-Moat Intellia Therapeutics Provides Pure-Play, Long-Term Exposure to Gene Editing Therapies
Intellia Therapeutics is a gene editing company focused on developing Crispr/Cas9-based therapies for genetically defined diseases. Its technology allows for precise cutting of DNA to disrupt, delete, correct, and insert genes. The company offers a pure-play, long-term investment opportunity in the gene editing space, targeting rare diseases and disorders caused by genetic mutations.
Tangible book value per share of Intellia Therapeutics, Inc. – HAN:38I
This article focuses on the tangible book value per share of Intellia Therapeutics, Inc. (HAN:38I), a biotechnology company listed on the Hannover Stock Exchange. It provides a financial overview, indicating that the market was closed with no trades at the time of publication, and highlights various data sources for financial information.
Intellia Therapeutics Stock Short Interest Rises to 41.97%
Intellia Therapeutics (NTLA) saw its short interest rise to 41.97% of the float on September 15th, an increase of 6.27% from August 31st, indicating growing bearish sentiment. Hedge funds showed mixed activity, with 187 institutional investors increasing their positions and 143 decreasing them, while company insiders made five sales and zero purchases in the last six months. Analysts have provided varying price targets for NTLA, with a median target of $17.0.
Does Priority Review Change The Bull Case For Intellia Therapeutics Stock (NTLA)?
Intellia Therapeutics has received Priority Review status from the FDA for its gene editing therapy, lonvo-z, for hereditary angioedema, signaling regulatory comfort and accelerating its path to commercialization. This development is expected to significantly impact the company's revenue mix and operating costs, moving it closer to profitability. While the Priority Review strengthens the investment narrative by focusing on a near-term regulatory outcome and extends the cash runway into 2027, potential risks include payer pushback, competition, and the challenge of scaling a one-time treatment.
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy
Intellia Therapeutics received FDA Priority Review for its Biologics License Application for lonvo-z, a gene-editing therapy for hereditary angioedema. This positions lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. and supports Intellia's strategy for earlier commercialization and revenue growth, although it also highlights concentration risk on the success of this single product.
Intellia Therapeutics (NTLA) Stock Jumped, What Is Behind The Latest Attention?
Intellia Therapeutics (NTLA) stock recently jumped after the FDA accepted its Biologics License Application for lonvo-z, a CRISPR-based hereditary angioedema therapy, and granted it Priority Review. Despite a 6.7% gain in one day and a 33.12% year-to-date return, the stock is considered significantly undervalued by Simply Wall St's fair value estimate of $23.94 against its current trading price of $12.26. However, its high P/S ratio of 28.9x, compared to peers and the US Biotech average, suggests potential valuation risk if revenue forecasts cool.
Intellia’s Lonvo-z Gains FDA Priority Review for HAE
Intellia Therapeutics announced that the FDA has granted Priority Review for its Biologics License Application (BLA) for lonvo-z, a one-time in vivo CRISPR therapy for hereditary angioedema (HAE), setting a PDUFA date of March 10, 2027. This decision follows positive Phase 3 HAELO trial data showing an 87% reduction in monthly HAE attacks. The FDA does not plan to convene an advisory committee, indicating a potentially streamlined path for lonvo-z to become the first in vivo CRISPR-based HAE treatment.
FDA grants lonvo-z priority review
The US FDA has accepted Intellia Therapeutics’ application for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR-Cas therapy, and granted it priority review. A phase 3 trial showed a single dose reduced hereditary angioedema attacks by 87% compared to placebo. If approved, lonvo-z could be the first authorized in vivo CRISPR-Cas therapy and a one-time treatment for hereditary angioedema.
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Intellia Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) for lonvo-z, a one-time gene editing treatment for Hereditary Angioedema (HAE), granting it Priority Review. The FDA set a PDUFA target action date of March 10, 2027, and does not plan to hold an advisory committee meeting. If approved, lonvo-z would be the world's first in vivo CRISPR-based therapy and the only one-time treatment for HAE, supported by positive Phase 3 HAELO clinical trial data showing an 87% reduction in monthly attacks.
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
Intellia Therapeutics shares rose 8% after the FDA granted Priority Review to its Biologics License Application for lonvo-z, a potential one-time CRISPR-based therapy for hereditary angioedema (HAE). The FDA set a target action date of March 10, 2027, for the drug, which demonstrated an 87% reduction in HAE attacks in its Phase 3 trial. This marks a significant step towards potentially introducing the world's first in vivo CRISPR-based treatment.
Intellia Secures $400M Credit Facility for NTLA-2002 HAE Trial
Intellia Therapeutics has secured a $400 million senior secured credit facility with OrbiMed to fund its global pivotal Phase 3 HAELO trial for NTLA-2002 (lonvo-z), a single-dose CRISPR therapy for hereditary angioedema. This financing strategy allows Intellia to fund the trial without immediately diluting shareholders, with the loan structured against future revenue or royalty streams. The move underscores the growing trend of CRISPR-based medicines moving into pivotal development and places emphasis on the HAELO trial's success and enrollment pace.
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Intellia Therapeutics, a biopharmaceutical company focused on CRISPR gene editing, announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. The company will present on Monday, September 14, 2026, at 4:05 p.m. ET, with a live webcast available on its investor relations website. A replay of the webcast will also be accessible for approximately 90 days.
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therapeutics has secured a non-dilutive senior secured term loan facility of up to $400 million with OrbiMed. This financing aims to provide Intellia with strategic flexibility as it advances its gene editing programs, particularly towards the potential U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). The facility includes an upfront funding of $75 million, with additional tranches tied to milestones for lonvo-z and other pipeline developments.
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therapeutics has secured a non-dilutive senior secured term loan facility of up to $400 million with OrbiMed to enhance its financial flexibility. The financing, with an initial $75 million funded upfront, will support the commercial launch of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE), advance nexiguran ziclumeran in transthyretin amyloidosis, and further early pipeline development. This strategic move aims to leverage lonvo-z's potential to transform HAE treatment and meet the company's future capital needs.
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Intellia Therapeutics, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, at 4:05 p.m. ET. The presentation will be webcast live on the company's investor relations website, with a replay available for 90 days. Intellia Therapeutics is a clinical-stage biopharmaceutical company focusing on CRISPR gene editing to develop curative treatments for severe diseases.
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Intellia Therapeutics, Inc. announced that it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET. A live webcast of the presentation will be available on the Investors & Media section of Intellia's website, with a replay accessible for approximately 90 days. The company, a clinical-stage biopharmaceutical firm, focuses on leveraging CRISPR gene editing to develop treatments for severe diseases.
Cathie Wood’s ARK buys Intellia stock, sells Brera holdings By Investing.com
Cathie Wood's ARK Invest has continued its accumulation of Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock, purchasing 39,548 shares worth over $504,000 through its ARKG ETF on September 3rd, 2026. This move aligns with ARK's recent bullish trend on Intellia, while simultaneously reducing its position in Brera Holdings PLC (NASDAQ:SLMT) by selling 10,853 shares across multiple ETFs, totaling $41,241. These trades reflect ARK's strategic portfolio adjustments, shifting focus towards Intellia Therapeutics and away from Brera Holdings.
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer LEONARD JOHN M
This document is a statement of changes in beneficial ownership of securities for Officer Leonard John M at Intellia Therapeutics. It reports alterations in his holdings of the company's securities, as required by regulatory guidelines.
Cathie Wood’s ARK buys Intellia stock, sells Roblox
Cathie Wood's ARK ETFs made significant portfolio adjustments on August 24, 2026. The firm invested heavily in Intellia Therapeutics (NTLA), purchasing 169,357 shares across its ARKK and ARKG ETFs. Concurrently, ARK continued to reduce its stake in Roblox Corp (RBLX), selling 26,199 shares, reflecting a strategic shift towards promising biotech stocks and away from gaming and entertainment.
Intellia Therapeutics (NTLA) CEO sells shares around $13
Intellia Therapeutics (NTLA) CEO John M. Leonard sold a total of 22,675 shares of common stock in August 2026 under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on August 20, 2026, and August 21, 2026, at weighted average prices around $12.60 to $13.00 per share, totaling approximately $287,000. Additionally, 58,415 shares are held indirectly by the John M. Leonard 2015 Irrevocable Trust.
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
This article highlights four gene-editing biotech stocks—CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), and Editas Medicine (EDIT)—as promising long-term investments. It details their differentiated technologies, clinical pipelines, and market positions, emphasizing gene editing's potential to revolutionize medicine by addressing diseases at their genetic source. While acknowledging the technology's transformative potential, the article also points out ongoing challenges related to delivery, safety, manufacturing, and regulatory approval.
Intellia Therapeutics Inc Stock Historical Valuations | XTER:38I
This page provides a stock summary for Intellia Therapeutics Inc (XTER:38I), including its current stock price (€11.1), market capitalization (€1.54B), P/B ratio (2.47), and enterprise value (€1.23B) as of August 21. It also notes that GuruFocus has detected three severe warning signs for the stock and offers a 7-day free trial to access more detailed analysis.
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
This document from Intellia Therapeutics is a "Notice of proposed sale of securities pursuant to Rule 144". It indicates that the company is filing a formal notice regarding the prospective sale of its securities, as required by SEC Rule 144.
John M. Leonard to sell 22,675 Intellia (NASDAQ: NTLA) shares
John M. Leonard, an officer and director at Intellia Therapeutics, Inc. (NASDAQ: NTLA), intends to sell 22,675 shares of common stock through UBS Financial Services Inc. The planned sale, with an aggregate market value of $293,641.25, is scheduled for August 20, 2026, and relates to shares acquired via stock option exercises in 2021. This information was disclosed in a Form 144 SEC filing.
Bank of America Corp DE Grows Stock Position in Intellia Therapeutics, Inc. $NTLA
Bank of America Corp DE increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 11.2% in the first quarter, now owning 1,381,703 shares valued at $17,713,000. Other institutional investors like Royal Bank of Canada and Arrowstreet Capital also significantly increased their positions. Despite insider sales from the CAO and an EVP, analysts have issued mixed ratings for NTLA, with a consensus "Hold" and a target price of $21.15.
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% - Here's What Happened
Intellia Therapeutics (NASDAQ:NTLA) saw its stock price rise by 10.7% during mid-day trading on Wednesday, though with lower-than-average trading volume. The company reported quarterly revenue of $7.66 million, missing estimates, while its adjusted loss of $0.80 per share matched expectations. Analysts have a mixed sentiment on the stock, with an average "Hold" rating and a price target of $21.15.
Trending Industry Today: Intellia Therapeutics Leads Gains In Gene Editing Stocks
Intellia Therapeutics (NTLA) is leading gains among gene-editing stocks, marking a significant upward trend within the industry. This performance highlights a positive movement for the company and potentially the broader gene-editing sector. The article focuses on NTLA's strong market performance and its implications for the industry today.
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative?
Intellia Therapeutics reported a net loss of US$106.63 million in Q2 2026 and a six-month net loss of US$202.87 million, both reduced from the prior year. This reduction in losses, alongside progress in its gene-editing pipeline like the positive Phase 3 results for lonvo z, may influence investor perception regarding cost management and the company's financial risk. Despite ongoing cash burn, the investment narrative is bolstered by regulatory momentum for lonvo z and analyst forecasts projecting significant revenue and earnings by 2029.
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative?
Intellia Therapeutics reported narrower six-month net losses and improved basic loss per share in Q2 2026, which may positively influence investor perception of its cost management. While ongoing cash burn and potential dilution remain risks, the progress of its gene-editing pipeline, especially promising Phase 3 results for lonvo z, is crucial for its investment narrative. The company's future success hinges on converting clinical data into regulatory approval and commercialization.
Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA
Wasatch Advisors LP significantly reduced its stake in Intellia Therapeutics Inc. by selling 134,215 shares, decreasing its holdings by 51.3%. Despite this, other institutional investors increased their positions in NTLA. The company currently holds a consensus "Hold" rating from analysts with an average price target of $21.15, and reported a Q2 loss of $0.80 per share, in line with estimates, though revenue missed expectations.
Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada
Royal Bank of Canada significantly increased its stake in Intellia Therapeutics (NASDAQ: NTLA) during the first quarter, now holding 465,499 shares worth approximately $5.97 million. The company reported a quarterly loss of $0.80 per share, meeting estimates, but revenue of $7.66 million missed expectations, declining 46.4% year over year. Institutional investors collectively own 88.77% of NTLA, and analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $20.85.
Intellia Therapeutics (NTLA) Could Be 50% Undervalued After Its Q2 2026 Earnings
Intellia Therapeutics (NTLA) reported Q2 2026 earnings, remaining in a loss-making position, though net loss and loss per share improved year-over-year. Despite recent stock volatility and a mixed long-term record, a narrative analysis suggests NTLA is approximately 50% undervalued with a fair value of $23.94, driven by expectations for its gene-editing pipeline and future approvals. However, the company faces significant risks including high R&D costs and reliance on trial outcomes, and its high P/S ratio indicates market expectations are already elevated.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% despite missing revenue forecasts in its latest quarterly report, with revenues of US$7.7m falling 41% short of expectations. Analysts have subsequently cut 2026 revenue estimates by a substantial amount to US$52.3m, although loss per share estimates remain steady at US$3.18. The average price target has also dropped 8.5% to US$23.94, reflecting concerns about the weaker revenue outlook and continued losses, and the company is expected to underperform the industry's revenue growth.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% following its latest quarterly results, despite revenues falling 41% short of expectations. Analysts have subsequently cut next year's revenue estimates significantly, while holding loss-per-share forecasts steady, leading to an 8.5% drop in the average price target to US$23.94. The company's revenue is now expected to decline by 23% by the end of 2026, underperforming the industry's projected 23% annual growth.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics, Inc. (NASDAQ:NTLA) recently reported its quarterly results, showing a significant revenue miss of 41% below analyst forecasts, though statutory losses were in line. Following these results, analysts have substantially cut next year's revenue estimates for Intellia Therapeutics by 12% to US$52.3m, while maintaining loss per share forecasts, and consequently, the average price target has fallen by 8.5% to US$23.94. The company is now expected to lag the wider industry's revenue growth, with its own revenues forecast to decline annually by 23% by the end of 2026.
Intellia Therapeutics (NTLA) Stock Rises As Pipeline Progress Lifts Sentiment
Intellia Therapeutics (NTLA) stock increased by 6.2% following its Q2 earnings report, signaling positive investor sentiment despite continued losses. The company's pipeline progress, particularly with Lonvo-z completing Phase 3 trials and Nex-z trials resuming, is driving optimism. While revenue declined and losses widened year-over-year, the narrowing loss per share and a cash pile providing runway into 2028 are key factors in the investment debate.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced inducement grants to eight new employees on August 1, 2026, consisting of 38,200 restricted stock units (RSUs) vesting over three years. These grants were made under Intellia's 2024 Inducement Plan and approved by the compensation committee as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on CRISPR gene editing.
State Street (NTLA) stake: 9.23M Intellia Therapeutics shares in 13G filing
State Street Corporation has disclosed a significant stake in Intellia Therapeutics (NTLA), reporting beneficial ownership of 9,234,987 shares, which represents 6.8% of the outstanding common stock. The filing, a Schedule 13G, indicates that State Street, along with its investment advisory subsidiaries, holds shared voting power over 8,907,136 shares and shared dispositive power over all 9,234,987 shares. This disclosure provides transparency regarding State Street's passive investment in Intellia Therapeutics.
Intellia Therapeutics | SCHEDULE 13G: Others
This article states that Intellia Therapeutics has filed a SCHEDULE 13G form with the SEC. The filing is categorized under "Others," indicating the nature of the report. This type of filing typically discloses beneficial ownership of shares.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced that on August 1, 2026, it awarded inducement grants to eight new employees. These grants consisted of time-based restricted stock units (RSUs) for a total of 38,200 shares of Intellia’s common stock, vesting annually over three years, and were made under Intellia’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for employment with the biopharmaceutical company.
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Revolution Medicines' pancreatic cancer drug daraxonrasib is seeing "significant demand" through a compassionate use program, leading analysts to raise sales projections. Intellia Therapeutics believes it has identified a genetic signature (HLA C*05:01 allele) linked to liver enzyme elevations in patients receiving its experimental gene editing treatment nex-z, potentially resolving a key safety concern. The article also provides updates on Arrowhead Pharmaceuticals' acquisition of a priority review voucher, a joint manufacturing facility between CSPC Pharmaceutical and AstraZeneca, and Vedanta Biosciences' new funding for a C. difficile trial.
Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ)
Evercore ISI upgraded Intellia Therapeutics (NTLA) to Outperform, citing promising new data on its rare-disease therapy, nex-z, developed in partnership with Regeneron (REGN). This upgrade led to a premarket rise in Intellia's stock on Friday.
Intellia Therapeutics, Inc. Stock 12‑Month Price Target Cut to $25.56, Implies 133% Upside
Intellia Therapeutics, Inc.'s average 12-month price target has been adjusted to $25.56 from $25.88 by 16 analysts, with a range between $8 and $95. This new target suggests a potential upside of approximately 133% based on the August 5th closing price. Despite the slight target reduction, the consensus rating from 19 analysts remains a "Buy."
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics (NTLA) reported progress in its gene-editing programs during Q2, including positive Phase III results for lonvo-z in hereditary angioedema (HAE) and resumed enrollment for nex-z in transthyretin amyloidosis. The company is preparing a BLA for lonvo-z, targeting FDA acceptance by late 2026 and potential U.S. launch in H1 2027. Intellia also discussed financial results, with $628.4 million in cash and equivalents, expecting to fund operations into at least 2028.
Intellia Therapeutics | 10-Q: Quarterly report
This document is the quarterly report (10-Q) filed by Intellia Therapeutics. Quarterly reports contain unaudited financial statements and provide a continuing view of the company's financial condition and results of operations.
Intellia Therapeutics Releases Q2 2026 Financial Results
Intellia Therapeutics, Inc. (NTLA) reported its Q2 2026 financial results, showing a narrower loss per share of -$0.80, which beat analyst estimates of -$0.82. Despite this, the company's collaboration revenue declined by 46.2% year-over-year to $7.7M, and it posted a net loss of $106.6M. Intellia continues to invest in its CRISPR-based therapeutics pipeline and is working to manage costs while advancing clinical programs.
Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating
Wedbush has revised its price target for Intellia Therapeutics (NTLA) down to $12 from $17, while keeping a Neutral rating on the stock. This adjustment follows the company's recent earnings report for the second quarter and six months ended June 30, 2026, where it reported a Q2 loss of $0.80 per share and revenue of $7.7 million. Intellia Therapeutics is a clinical-stage gene editing company developing CRISPR-based therapies for conditions like hereditary angioedema and transthyretin amyloidosis.
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates
Intellia Therapeutics Inc (NASDAQ: NTLA) reported second-quarter earnings per share (EPS) that matched analyst estimates at $-0.80, but its revenue of $7.66 million fell short of the consensus estimate of $13.18 million. The company's stock price has declined by 22.14% over the last three months and 4.28% over the past year. InvestingPro rates Intellia Therapeutics Inc's financial health as "fair performance."
